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Abstract 
Introduction: Paragangliomas are usually benign tumors arising from chromaffin cells located outside the adrenal gland. Prostatic 
paraganglioma is an unusual entity in adult patients, with only 10 cases reported in the medical literature.
Case report: A 34-year-old male with a history of chronic prostatitis consulted for perineal pain. On digital rectal examination the 
prostate was enlarged and firm, without nodules. The PSA level was 0.8 ng/mL and the catecholamines in the urine were elevated. On 
ultrasound a retrovesical 9 cm mass of undetermined origin measuring was present. A PET-CT scan showed a pelvic lesion measuring 
9 cm with moderate increase in glucidic metabolism localized in the area of the prostate. A biopsy of the prostate revealed a neuroen-
docrine tumor, possibly a prostatic paraganglioma. A body scintigraphy with MIBG I-123 ruled out the presence of metastases or 
multifocal tumor. A radical prostatectomy with excision of the pelvic mass was performed under adrenergic blockade. One year after 
surgery the patient is asymptomatic and disease free.
Discussion/conclusions: Prostatic paraganglioma is a rare, usually benign tumor, which should be considered in the differential diag-
nosis of prostate tumors in young males. Its diagnosis is based on the determination of catecholamine in blood and 24-hour urine and 
in imaging studies principally scintigraphy with MIBG I-123. Diagnostic confirmation is by histopathological study. The treatment 
consists of radical resection under adrenergic blockade and volume expansion. Given the limited number of cases reported, it is difficult 
to establish prognostic factors. Malignancy is defined by clinical criteria, and requires life long follow-up.
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Introduction
Paragangliomas are tumors arising from chromaffin 
cells located outside the adrenal gland. They develop 
in the paraganglion system, which originates in the 
neuroendocrine cells migrated from the neural crest, 
along with the autonomic nervous system. Generally 
they are benign, slow growing neoplasms, although 
malignant behavior and distant metastases has been 
described.  Prostatic  paraganglioma  is  an  unusual 
entity  with  10  reported  cases  in  adult  males.  We 
present the case of a 34-year-old patient diagnosed 
with chronic prostatitis in which this type of neoplasm 
was identified.
case Report
A 34-year-old male consulted for intermittent non-
radiating  perineal  pain  of  2  months  duration.  The 
past history was significant for symptoms of chronic 
prostatitis that responded well to non-steroidal anti-
inflammatory drugs for the past 4 years. On physical 
examination the abdomen was soft without masses or 
organomegaly. A digital rectal examination revealed 
a large and rubbery mass in the area of the prostate. 
The serum PSA was 0.8 ng/mL. An abdominal ultra-
sound revealed a retrovesical mass measuring 9 cm 
in diameter of undetermined origin. On CT scanning 
an heterogeneous mass measuring 90 × 88 × 75 mm 
with well-defined borders located below and behind 
the bladder, which was anteriorly displaced was seen. 
The origin of the mass appeared to be the prostate. 
Neither  abdominal  nor  pelvic  pathological  lymph 
nodes, nor bone lesions were observed (Fig. 1).
A prostate biopsy was performed, which showed 
bilateral infiltration by a neuroendocrine tumor with 
a low proliferation index (Ki67 index below 1%) sug-
gestive of paraganglioma of possible prostatic origin.
Determination  of  catecholamine  and  its  metabo-
lites  in  24-hour  urine  yielded  the  following  results: 
Vanillylmandelic acid 22.2 mg/24 h (reference value: 
2.0–9.0), adrenaline 47 µg/24 h (,18), noradrenaline 
158 µg/24 h (,76) and dopamine 285 µg/24 h (,390).
PET-CT with injection of 150 µCi/kg of 18F-FDG 
showed  a  pelvic  lesion  of  9  cm  with  a  moderate 
increase in glucidic metabolism located in the prostate 
site and ascending to the vesico-rectal region (SUV 
max 3.6), not demonstrating other evident pathologi-
cal deposits of the radio-medicine FDG, discarding a 
multifocal or disseminated disease (Fig. 2).
The body scintigraphy with 4 mCi of 123 I meta-
iodobenzylguanidine (MIBG), with images 4 hours 
after  administration  in  the  adrenal  area  and  after 
twenty-four hours in the rest of the body found no 
significant alterations.
Six weeks after performing the study, the patient 
suffered intermitent episodes of cold sweats and ele-
vated blood pressure (200/120 mmHg), lowered heart 
rate (50 beats/minute), dyspnea with minimal activity, 
and asthenia, which began five minutes after micturi-
tion or defecation and were self-limited. Treatment 
with Doxazosin mesylate was initiated. The symp-
toms worsened with constipation or if the patient for-
got to take the alpha-blockers. Phenoxyibenzamine 
at progressively higher doses and Propanolol, were 
added to control the symptoms.
Eight weeks after the initial consultation, a radical 
prostatectomy with excision of the pelvic mass and 
preservation of the neurovascular bundles was per-
formed under adrenergic blockade. The postoperative 
recovery  was  uneventful  and  the  patient  was  dis-
charged on post-operative day 8 with normal blood 
pressure on no medications.
Macroscopically,  a  multinodular  ovoid  mass 
weighting 181 grams and measuring 9 × 7 × 5.5 cm 
was described. The external surface was smooth and 
shiny  with  partly  greyish  partly  violet  coloration. 
When cut, a lesion of a mostly brown or copper col-
oration with areas of softening and central cavitation 
which replaced the normal prostatic parenchyma was 
found. An abrupt or clear separation between the path-
ological and normal prostate tissue was not observed, 
but rather a gradual transition.
The histological analysis of the specimen revealed a 
neoplasm with imprecise limits and a epithelioid appear-
ance with predominant growth by nests constructed of 
cuboidal cells (“Zellballen”) with granular basophilic 
cytoplasms  and  small  sized  nuclei,  mostly  homog-
enous, and of a rounded-ovoid morphology. Peppered 
in and among them, appear cells with bizarre nuclei 
Figure 1. CT scan.paraganglioma of prostatic origin
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of greater cytological atypia, and other rounded nuclei 
with reinforced nuclear membranes, with evident cen-
tral nucleolus. These cells have higher density polygo-
nal eosinophyllic cytoplasm with a ganglionic habit. 
Immunostaining  revealed  expression  for  Vimentin, 
Synaptophysin, chromogranin and ENE, being negative 
for PSA and AE1/AE3. The proliferation index (MIB.1) 
of the cells is very low. In addition, and in a charac-
teristic way, the nests appear surrounded by fibrous 
septa, with sustentacular cells (S.100+), with elongated 
nuclei and badly defined spindles and cytoplasm. The 
growth of the lesion causes hyaline fibrosis in the pro-
static stroma, with focal neural (multifocal perineural 
growth) and glandular preservation. The rest of the 
prostatic parenchyma had its habitual structure without 
a well-defined transition with the neoplasia. The semi-
nal vesicles showed neither infiltration nor histological 
lesions. These characteristics allow the classification of 
the lesion as a neuroendocrine tumor with histological 
and  immunostaining  characteristics  compatible  with 
prostatic paraganglioma (Figs. 3 and 4).
Three months after surgery the patient has got urinary 
continence and normal blood pressure but suffers from 
erectile dysfunction. A scan with Octreotide In-111 showed 
no pathological tracer deposits expressing Somatostatin 
receptors in the planar body images and SPECT-CT of 
abdomen at 6 and 24 hours after the administration of 
a dose of radio-medical tracer were observed. One year 
after surgical treatment he has normal micturition and 
blood pressure but persistent erectile dysfunction.
Discussion
Paragangliomas are slow growing neoplasms derived 
from the paraganglion tissue.1 They consist of neu-
roendocrine  cells  derived  from  the  neural  crest 
along the autonomic nervous system and associated 
with  abundant  vascularization.  According  to  the 
anatomical location they can be grouped into bran-
chiomeric, intravagal, aortic-sympathetic and auton-
omous-visceral paragangliomas.2
Approximately  90%  grow  in  the  adrenal  gland 
and are called pheochromocytomas. The other 10% 
Figure 2. peT-TC scan.padilla-Fernández et al
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are non-adrenal paragangliomas, of which 85% are 
abdominal.  Of  these  last,  approximately  88%  are 
para-aortic (next to the adrenal gland and the renal 
hilum, and at the Zuckerkandl organ and are more 
frequent in adults) and the rest, almost all are found 
in the bladder, mostly in pediatric patients.3,4 There 
are 10 cases of prostatic paraganglioma documented 
in medical literature which arise in the sympathetic 
paraganglionic tissue located in the soft tissue besides 
and behind the gland.5–7 (Table 1).
Generally, paragangliomas affect young adults of 
both sexes equally, although cases of prostatic para-
ganglioma have been encountered in children.10 The 
symptoms are varied and are related to the size and 
location of the lesion, as well as to the tumor’s capac-
ity to secrete catecholamines. In the case of prostate 
paragangliomas, the most frequent local symptoms are 
hematuria and moderate perineal pain, but other asso-
ciated symptoms are derived from the production of 
vasoactive amines such as treatment-resistant hyper-
tension, as well as the presentation of hypertensive 
crisis triggered by micturition, defecation or a digital 
rectal examination.18
It should be taken into consideration that up to 50% 
of paragangliomas are hereditary and can be associ-
ated  with  diseases  like  type  1  neurofibromatosis, 
familial paraganglioma, von Hippel-Lindau disease 
and the Carney’s triad.19
Diagnostic confirmation is accomplished through 
the  determination  of  catecholamine  and  its  deriva-
tives in serum or urine of 24-hours and body scintig-
raphy  with  I123-meta-iodobenzylguanidine  (I123-MIBG).20   
Other image tests such as CT, PET-CT or MRI can help 
to establish the diagnosis and locate the lesion.
In the revised literature, it is not recommended to 
perform a diagnostic biopsy due to the possibility of 
triggering a hypertensive crisis both in prostate and 
bladder pargangliomas,21 although the frequent scar-
city of symptoms and indicators of this pathology 
mean that on occasion we can’t meet this criteria.
The treatment of choice in the case of localized 
and solitary tumor is the complete surgical resection 
under adrenergic blockage and volume expansion, in 
a similar fashion as in adrenal pheochromocytomas.22 
Radiotherapy has also been recommended, although 
its best indication is in the palliative treatment of the 
pain associated with bone metastases lesions.1
All paragangliomas share the same histological 
characteristics  independent  of  the  site  of  origin.23 
They show a pattern of nests and cords (Zellballen) 
surrounded by fine fibrovascular tracts. Other less 
frequent  patterns  exist  and  they  are  usually  focal 
such  as  angiomatoid,  spindle-cell,  clear  cell  and 
sclerosing.
Figure 3. Hematoxylin-eosin 10× and 20×.
Figure 4. Inmunostaining (Vimentin, Synaptophysin, S100 10×).paraganglioma of prostatic origin
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The lesions are composed of two types of cells: the 
principal and sustentacular cells. The majority of the 
cells  have  a  rounded  and  ovoid  nucleus  with  finely 
granular chromatin and occasional nucleolus, with a 
salt-and-pepper appearance. Their cytoplasm is large, 
polygonal, eosinophilic and finely granular, and can 
occasionally be pigmented. Immunostaining is positive 
for neuroendocrine markers (synaptophysin, chromogr-
anin A, neural-specific enolase CD 56 and serotonin). 
The sustentacular cells have a hyperchromatic nucleus 
and  a  flattened  and  elongated  cytoplasm;  they  are 
characteristically positive for S100.23
The principal differential diagnosis for this pathol-
ogy  is  high  grade  adenocarcinoma  of  the  prostate. 
Negative results in inmunostaining for PSA, prostate-
specific acid phosphatase, cytokeratin 7, cytokeratin 20, 
cytokeratin  903  and  thrombomodulin,  along  with 
positive results for chromogranin, synaptophysin and 
S100 are clear differential diagnostic criteria.14
In  general  they  are  tumors  of  benign  nature, 
but 10% of cases have been reported as malignant 
neoplasms  with  extensive  local  infiltration  and  a 
high tendency towards the development of distant 
metastases in bones, lymph nodes and heart, there-
fore life-long follow-up is needed.10,24 In addition, 
its insidious course with a lack of specific symp-
toms in many patients makes the diagnosis of the 
tumor difficult until an advanced stage.14 Given that 
the size and location of these tumors stand out as 
important prognostic factors, its early diagnosis is 
fundamental.1  However  histological  features  pre-
dicting  paragangliomas’  behavior  have  not  been 
defined, but possibly the presence of a high level of 
mitotic activity, large areas of necrosis and evidence 
of vascular invasion might be useful to predict their 
evolution.23,25
conclusions
Prostatic  paraganglioma  is  an  unusual  pathology, 
generally benign, which should be considered in the 
differential  diagnosis  of  prostate  tumors  in  young 
males.
Its diagnosis is based on the determination of cat-
echolamine in 24-hour blood and urine and in imag-
ing techniques mainly body scintigraphy with MIBG 
I-123. Diagnostic confirmation is achieved through a 
histopathological study.
Treatment  consists  of  radical  resection  of  the 
pelvic mass under adrenergic blocking and volume 
expansion.  Radiotherapy  is  useful  in  palliative 
treatment.
Given the scarcity of documented cases, it is diffi-
cult to establish the prognosis for patients affected by 
this pathology. Its malignancy is defined by clinical 
criteria, which indicates life-long follow-up to elimi-
nate the possibility of relapses.
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